Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2020-04-07 Earnings Release
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
2020年第一季度业绩预告
Earnings Release Classification · 95% confidence The document is a 2020 first quarter earnings forecast (业绩预告) for Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It provides estimated net profit figures for the period January 1 to March 31, 2020, compared to the same period in 2019. The document explicitly states that the forecast is unaudited and that detailed actual data will be disclosed in the company's first quarter report. The document is short (970 characters) and serves as an earnings preview rather than a full financial report. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly financial results with key highlights only. Q1 2020
2020-04-07 Chinese
独立董事2019年度述职报告（刘光福）
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of Anhui Anke Biotechnology (Group) Co., Ltd. for the year 2019. It describes the director's duties, attendance at board meetings, independent opinions on board matters, participation in audit and supervisory committees, and efforts to protect investor rights. The content focuses on governance, oversight, and compliance activities rather than financial results or earnings. It is not an announcement or a brief notice but a substantive report on the director's activities and governance role. This aligns with the category of Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management activities. The document is not an Annual Report, Audit Report, or Regulatory Filing, as it does not contain financial statements or audit opinions but rather a governance-related report by an independent director.
2020-04-07 Chinese
国元证券股份有限公司关于公司全资子公司安徽安科余良卿药业有限公司受让控股子公司部分股权暨关联交易的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding a related-party transaction involving a subsidiary of Anhui Anke Bioengineering (Group) Co., Ltd. It includes information about the transaction, parties involved, financial data of the target company, pricing policy, approvals by the board and independent directors, and the sponsor's verification opinion. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a regulatory announcement about a related-party transaction and the sponsor's due diligence opinion. This type of document fits best under Regulatory Filings (RNS), as it does not match other specific categories such as M&A Activity or Capital/Financing Update, and is not a full financial report or earnings release.
2020-04-07 Chinese
国元证券股份有限公司关于公司《2019年度内部控制自我评价报告》的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from Guoyuan Securities regarding Anhui Anke Bioengineering (Group) Co., Ltd.'s 2019 Internal Control Self-Evaluation Report. It references regulatory requirements and standards for internal control and corporate governance, and it provides an audit-like opinion on the internal control report's completeness, reasonableness, and effectiveness. The document is not the internal control report itself but an independent verification or audit opinion on that report. It does not contain full financial statements or comprehensive financial data, nor is it a full annual or interim report. It is a standalone audit-related document focused on internal control evaluation, fitting the definition of an Audit Report / Information (AR). The document length is 3572 characters, which is relatively short but contains substantive content beyond a mere announcement or certification. Therefore, the best classification is AR with high confidence. FY 2019
2020-04-07 Chinese
国元证券股份有限公司关于公司2019年度募集资金存放与使用情况的专项核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report by Guoyuan Securities Co., Ltd. (the sponsor) on the 2019 annual special audit opinion regarding the deposit and use of raised funds by Anhui Anke Biotechnology (Group) Co., Ltd. It includes specifics on the amount of funds raised, timing, usage, balance, management, and compliance with regulatory requirements. It also references a verification report by an accounting firm and the sponsor's audit work and opinions. The document is focused on the use and management of funds raised through a non-public issuance of A shares in 2019, with detailed financial figures and compliance statements. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not a full annual report, audit report, or earnings release, but a specialized report on fundraising usage and compliance. The length (4988 characters) and content indicate it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2020-04-07 Chinese
独立董事对相关事项之事前认可意见
Audit Report / Information Classification · 95% confidence The document is a formal opinion from independent directors regarding the pre-approval of certain company matters, including the reappointment of the audit firm for the 2020 fiscal year and related party transactions. It references regulatory guidelines from the China Securities Regulatory Commission and stock exchange rules. The document does not contain financial statements or detailed audit results but rather expresses the independent directors' approval opinions on specific corporate governance and audit-related matters. This type of document aligns with an Audit Report / Information filing, as it relates to audit firm reappointment and related audit matters, but is not a full annual report or audit report itself. Given the content and length, the best classification is AR (Audit Report / Information). FY 2019
2020-04-07 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.